Claim OwnershipVJOncology Podcast
Subscribed: 17Played: 853
Subscribe
© Copyright 2022 All rights reserved.
Description
The Video Journal of Oncology (VJOncology) podcast covers the latest solid oncology news from international experts, including breast, lung, skin, genitourinary, head and neck, gynecological and more.
Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion.
If you enjoy the podcast, please leave us a rating and review!
For more news visit www.vjoncology.com
Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion.
If you enjoy the podcast, please leave us a rating and review!
For more news visit www.vjoncology.com
203 Episodes
Reverse
In this week’s VJOncology podcast, we have the pleasure to bring you key updates in gastrointestinal cancer at ESMO 2025, which we attended live in Berlin. Join esteemed experts Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, Michele Reni, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, and Anwaar Saeed, MD, University of Pittsburgh, Pittsburgh, PA, as they discuss ground-breaking trials such as FORTITUDE-101, CASSANDRA, STELLAR-303, and more.
In this episode of the VJOncology Podcast, we bring you four standout interviews from ESMO 2025 that are reshaping the way we think about lung cancer. From antibody-drug conjugates and bispecific T-cell engagers through novel HER2-targeted TKIs to tumour-immune microenvironment biomarkers, the treatment paradigm is evolving rapidly.
Join us as we explore findings from the Phase III OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutant non-small-cell lung cancer (NSCLC) post-TKI progression, safety analysis of DeLLphi-304: tarlatamab vs standard chemo in small-cell lung cancer (SCLC), the first-line Beamion LUNG-1 experience of zongertinib in advanced HER2-mutant NSCLC and biomarker insights from the ImmunoDriver-2 analysis.
We’ll weave together how these advances hint at a future where molecular and immunologic profiling come together: identifying patients who will benefit most, integrating new treatment classes, and navigating safety/survivorship in more complex regimens.
In this week’s podcast from VJOncology, leading experts share key insights from the 44th Congress of the European Society of Surgical Oncology (ESSO 44), held in Gothenburg, Sweden. The meeting brought together global specialists to discuss innovations in cancer surgery, including artificial intelligence, robotics, and fluorescence imaging.
Beate Rau, MD, PhD, highlights advances across gastrointestinal and rectal cancers, as well as the role of intraperitoneal chemotherapy in gastric cancer. Marco Fiore, MD, discusses the evolving surgical approach to retroperitoneal sarcoma, while Piotr Rutkowski, MD, explores progress in melanoma management, from gene expression profiling to new targeted treatments. Gabrielle van Ramshorst, MD, outlines the essential skills for the next generation of colorectal surgeons, and Domenico D’Ugo, MD, reflects on the concept of the mesogastrium and its implications for radical gastric cancer surgery.
In this week’s VJOncology podcast, leading experts share the latest updates in ADCs in HER2-positive and metastatic breast cancer in recognition of Breast Cancer Awareness Month.
Charles Geyer, MD, discusses pivotal results from the Phase III DESTINY-Breast05 trial, where trastuzumab deruxtecan (T-DXd) significantly improved invasive disease-free and disease-free survival versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer, reducing the risk of brain metastases. Sara Tolaney, MD, MPH, highlights the practice-changing reduction in recurrence risk with T-DXd and comments on the expanding role of antibody–drug conjugates (ADCs) in earlier lines of therapy across breast cancer subtypes, referencing data from DESTINY-Breast09 and ASCENT-03. Finally, Erika Hamilton, MD, reviews the advancement of ADCs into the curative setting through DESTINY-Breast11 and discusses emerging combination strategies and first-line use in triple-negative breast cancer, emphasizing the growing importance of ADCs in modern breast cancer care.
In this week’s VJOncology podcast, leading experts share key updates presented at the ESMO 2025 Congress in Berlin, Germany.
Sara Tolaney, MD, MPH, highlights the expanding role of ADCs in earlier lines of metastatic breast cancer, presenting data from the DESTINY-Breast09 and ASCENT-03 trials, and discusses results from DESTINY-Breast05, where trastuzumab deruxtecan demonstrated superior outcomes to trastuzumab emtansine in high-risk HER2-positive early breast cancer. Scott Tagawa, MD, reports findings from the PSMAddition trial of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer, showing improved radiographic progression-free survival. Antonio Passaro, MD, PhD, outlines data from the OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutated NSCLC, establishing a new benchmark for TROP2-directed ADCs. Andrea Necchi, MD, discusses interim results from the RC48-C016 trial supporting disitamab vedotin plus toripalimab in HER2-expressing urothelial carcinoma, and Sapna Patel, MD, shares encouraging early findings on PRAME-directed TCR therapy in uveal melanoma.
In this week’s VJOncology podcast, leading experts share the latest updates in the management of hepatocellular carcinoma (HCC) in recognition of Liver Cancer Awareness Month.
Stephen Lam Chan, MD, FRCP, discusses emerging immunotherapy and targeted approaches, including novel TIM3 and TIGIT inhibitors, and findings from the SIERRA study of durvalumab and tremelimumab in advanced HCC. Lorenza Rimassa, MD, reviews the CheckMate 9DW trial establishing nivolumab plus ipilimumab as a new standard of care, while Qi Cheng, PhD, highlights promising results from a Phase II study of irpagratinib plus atezolizumab in FGF19-positive HCC. Ciro Celsa, MD, PhD, shares real-world data from the DT-REAL study evaluating durvalumab with or without tremelimumab in unresectable HCC, confirming the regimen’s effectiveness in clinical practice. Finally, Marina Baretti, MD, presents encouraging findings from a Phase I study of a peptide vaccine targeting the DNAJB1-PRKACA fusion in fibrolamellar HCC.
In this week’s VJOncology podcast, we are joined by brain tumor experts Stephen Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA, and Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, as they discuss the latest updates in cerebrospinal fluid (CSF) liquid biopsies in brain tumors. They will comment on the rationale and challenges in CSF liquid biopsies in this space, current research in their clinical utility and what the future holds for this area.
In this week’s exclusive VJOncology podcast, we are joined by Javier Martín-Broto, MD, PhD, Fundación Jiménez Díaz University Hospital, Madrid, Spain, who shares expert insights on the evolving role of immunotherapy in sarcoma. He discusses the unique immunosensitivity of alveolar soft part sarcoma, the potential of combining checkpoint inhibitors with anti-angiogenic or anti-CTLA-4 agents, and encouraging results with TCR-T cell therapy in synovial sarcoma and myxoid liposarcoma. The role of biomarkers such as tertiary lymphoid structures (TLS) is also highlighted as a predictor of response to immunotherapy.
In this week’s VJOncology podcast, we have the pleasure to bring you key updates in lung cancer at IASLC 2025 World Conference on Lung Cancer (WCLC), which we attended live in Barcelona, Spain. Join experts John Varlotto, MD, Marshall University, Huntington, WV, Alessio Cortellini, MD, Bio-Medico University, Rome, Italy, Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, Nicolas Girard, MD, Institut Curie, Paris, France, and Kenneth O'Byrne, MD, MB, BCh, Princess Alexandra Hospital, Brisbane, Australia, as they discuss pivotal trials in non-small cell lung cancer (NSCLC) such as the FLAURA2, and ACROSS 2 trials, developments in mesothelioma, and practice-changing data in small cell lung cancer (SCLC).
In this week’s podcast from VJOncology, three leading experts provide insights into the latest advances in precision medicine for head and neck cancer.
Luigi Lorini of Humanitas Research Hospital discusses the evolving treatment landscape of immunotherapy in head and neck squamous cell carcinoma. Danny Rischin of the Peter MacCallum Cancer Centre presents findings from a Phase II trial evaluating fianlimab plus cemiplimab in patients with recurrent or metastatic PD-L1–expressing head and neck squamous cell carcinoma. Finally, Jun Ma from Sun Yat-sen University Cancer Center explores the future of immunotherapy in nasopharyngeal carcinoma beyond PD-1 and shares results from the Phase III DIAMOND trial of toripalimab with induction chemotherapy and radiotherapy, with or without concurrent cisplatin, in locoregionally advanced disease.
In this week’s VJOncology podcast, we will be joined by Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, as he outlines current and emerging strategies for managing HER2-positive metastatic breast cancer after antibody–drug conjugate (ADC) therapy, with a focus on trastuzumab deruxtecan (T-DXd). He discusses the use of tucatinib-based regimens, mechanisms of resistance to agents such as trastuzumab emtansine (T-DM1), and approaches to treating brain metastases, drawing on evidence from trials. The importance of individualized treatment is highlighted, particularly in hormone receptor–positive disease, where CDK4/6 inhibitors may provide added benefit.
In this week’s installment of the VJOncology podcast, we will examine the cutting-edge applications of artificial intelligence in clinical oncology. This episode presents a curated series of expert insights into AI-driven tools for early detection, diagnostic precision, biomarker development, treatment guidance, and prognostic assessment. Leading clinicians and researchers discuss breast, sarcoma, kidney, gastric, and lung cancers, highlighting how AI is being integrated into clinical workflows, risk stratification, and patient-specific decision-making. This episode provides actionable knowledge on leveraging AI to improve diagnostic accuracy, optimize therapeutic strategies, and enhance patient outcomes across multiple tumor types.
Join leading GI cancer experts J. Randolph Hecht, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jasmine Mitchell, UCLA Santa Monica Medical Center, Santa Monica, CA, and Jingran Ji, UCLA Santa Monica Medical Center, Santa Monica, CA, as they share key insights from the most impactful gastrointestinal cancer updates presented at ASCO 2025.
In this episode, they discuss pivotal trials including CHALLENGE (NCT00819208), demonstrating that structured exercise can improve disease-free survival in resected colon cancer; ATOMIC (NCT02912559), highlighting the role of adjuvant immunotherapy with atezolizumab in MSI-high colon cancer; and MATTERHORN (NCT04592913), where adding durvalumab to perioperative FLOT improved outcomes in gastric and gastroesophageal junction adenocarcinoma.
In this week's VJOncology podcast, we will be covering highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 in Chicago, IL. Gain expert insight on exploratory biomarkers, treatment landscape shifts, and practice-changing trials from leading researchers in the field of genitourinary cancers.
Join renowned speakers Angela Jia, Tian Zhang, Michael Harrison, Margaret Gatti-Mays, and Stefanie Zschaebitz, as they discuss Phase I/II trial results on neoadjuvant combination therapy for cisplatin-ineligible bladder cancer, and strides in personalized vaccines in metastatic prostate cancer.
In this episode of the VJOncology podcast, we explore the evolving landscape of gynecologic cancer care with expert insights recorded at the 2025 ESMO Gynaecological Cancers Congress in Vienna. Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses new data from the RUBY trial and the impact of dostarlimab in endometrial cancer. Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, presents findings from the TRUST trial, highlighting the value of primary debulking surgery in advanced ovarian cancer. We also hear from Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany on overcoming treatment hesitancy in elderly ovarian cancer patients, and Angeles Secord, MD, Duke Cancer Institute, Durham, NC shares promising results from the PICCOLO study of mirvetuximab soravtansine in FRα-positive disease. Finally, Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, outlines a new standard of care for stage 3 cervical cancer, combining radiotherapy with pembrolizumab as supported by KEYNOTE-A18. Tune in for expert commentary and clinical implications that could shape the future of gynecologic oncology.
In this weeks podcast from VJOncology, five leading experts share updates and insights on the evolving landscape of precision medicine in sarcoma.
Robin Jones discusses the complexities of implementing precision medicine and presents results from a Phase III trial of catequentinib in advanced leiomyosarcoma. Javier Martín-Broto explores recent advances in immunotherapy and shares findings from Cohort 7A of the ImmunoSarc2 trial, evaluating epirubicin and ifosfamide plus nivolumab in undifferentiated pleomorphic sarcoma. Nadia Hindi highlights Cohort 2, which assessed sunitinib and nivolumab in extraskeletal myxoid chondrosarcoma. Ramya Ramaswami addresses unmet needs in Kaposi sarcoma and presents data from a Phase I trial of efineptakin alfa in patients with and without HIV. Finally, Brian Van Tine discusses a Phase II trial of olaparib and temozolomide in advanced uterine leiomyosarcoma.
In this weeks VJOncology podcast, we have the pleasure to bring you key updates in CAR-T and cellular therapies in brain tumors. Gain expert insights on landmark trials, treatment advances, and shifting screening practices from some of the foremost voices in the field. Topics of discussion include a Phase I trial of intracranial B7H3-directed CAR-T cell therapy in patients with recurrent glioblastoma, effective strategies in anti- glioblastoma CAR-T cells, and dendritic cell therapy in recurrent glioblastoma.
This week’s VJOncology podcast episode highlights four breakthrough studies from ESMO GI 2025 in Barcelona, Spain, featuring expert insights on gastrointestinal cancer advances. Coverage includes the EXPEL PANC study combining BXCL701 with pembrolizumab for pancreatic cancer, SIERRA study safety data on the STRIDE regimen for hepatocellular carcinoma, TALENTACE trial results combining TACE with atezolizumab plus bevacizumab, and updated MATTERHORN study data on perioperative immunotherapy for gastric cancer. Leading oncologists share perspectives on these game-changing developments reshaping GI cancer treatment live from Barcelona, Spain.
Join esteemed experts Joao Victor Alessi, Hospital Sírio-Libanês, Sao Paolo, Brazil, and Alessandro Di Federico, Dana-Farber Cancer Institute, Boston, MA, as they discuss the most anticipated updates in lung cancer presented at ASCO 2025, as they comment on ground-breaking trials and provide their insights on the significance of the findings and updates.
In this episode, they comment on the potential of new agents like tarlatamab, and pivotal trials such as the OptiTROP-Lung03 trial of sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer (NSCLC), the CheckMate 816 trial of neoadjuvant nivolumab plus chemotherapy, and the ALNEO trial of alectinib in ALK-positive NSCLC.
Join our experts as they delve into the latest advancements in breast cancer presented at ASCO 2025, as they comment on highly anticipated trials and gives their perspectives on the significance of the findings and updates.
In this episode, Kevin Kalinsky, Emory University Hospital, Atlanta, GA, and Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY, receive updates on trials presented at this year’s ASCO, including the ASCENT-04 trial (NCT05382286) of sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC) and the DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ breast cancer.
Comments
Download from Google Play
Download from App Store
United States